Inspire
is a biopharmaceutical company focused on researching, developing and commercializing
prescription pharmaceutical products for ophthalmic and pulmonary diseases.
Inspire's goal is to build and commercialize a sustainable portfolio of innovative
new products based on its technical, scientific and commercial expertise. Inspire's
clinical pipeline includes denufosol tetrasodium for cystic fibrosis in Phase
3 development and AZASITE® (azithromycin ophthalmic solution) 1% for blepharitis
in Phase 2 development. Inspire receives revenues related to the promotion of
AZASITE® for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine
HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based
on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry
eye.
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
DURHAM, N.C., Sep 01, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the appoin...
Inspire Announces Amendment to Ophthalmic Collaboration
DURHAM, N.C., Aug 25, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has ent...
Inspire Names Dr. Charles Johnson as Executive Vice President of Research and Development and Chief Medical Officer
- Experienced Pulmonologist and Cystic Fibrosis Drug Development Expert Joins Inspire -
DURHAM, N.C., Aug 13, 2010 ...
Inspire Announces Webcast of Presentation at Bank of America Merrill Lynch Specialty Pharmaceuticals Conference
DURHAM, N.C., Aug 05, 2010 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Adria...
© Inspire Pharmaceuticals 2010 All Rights Reserved
Terms of Use Legal Notices
Page Updated on: 8/26/2010
